Tags : Cardiovascular Safety

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat

Tuba Khan November 11, 2019

Shots: The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9,000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca, FibroGen and Astellas […]readmore

Pharma

AstraZeneca Reports Results of Roxadustat in Global Phase III Programme

Tuba Khan May 10, 2019

Shots: The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9,000+ patients with anemia + CKD not on dialysis (NDD) , dialysis-dependent (DD), ID respectively […]readmore

Tags : Cardiovascular Safety

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat

AstraZeneca Reports Results of Roxadustat in Global Phase III Programme

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Cardiovascular Safety

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat

AstraZeneca Reports Results of Roxadustat in Global Phase III Programme

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company